All these factors play a crucial role in atherogenesis13, and their reduction during MVC intensification underlines the positive effects of CCR5 inhibitors in reducing the progression of the atherosclerosis process in HIV-infected patients. The gene discussed is CCR5; the disease is atherosclerosis.